Technology insight: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 2, 2005, Pages 96-102

  Lundberg, Jon O ^a   Hellström, Per M ^a   Fagerhol, Magne K ^b   Weitzberg, Eddie ^a   Roseth, Arne G ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Calprotectin; Fecal marker; Inflammatory bowel disease; Lactoferrin; Nitric oxide

Indexed keywords

AZATHIOPRINE; CALPROTECTIN; GLUCOCORTICOID; INFLIXIMAB; LACTOFERRIN; MESALAZINE; NITRIC OXIDE; SALAZOSULFAPYRIDINE;

CHILD CARE; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; IRRITABLE COLON; LABORATORY TEST; LONG TERM CARE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SCREENING; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; NITRIC OXIDE;

EID: 20344382725     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0094     Document Type: Review

References (52)

1. Suleiman S and Sonnenberg A (2001) Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch Intern Med 161: 369-375
2. Saverymuttu SH et al. (1986) Indium 111-granulocyte scanning in the assessment of disease extend and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 90: 1121-1128
3. Weldon MJ et al. (1996) Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Aliment Pharmacol Ther 10: 123-132
4. Saverymuttu SH (1986) Clinical remission in Crohn's disease-assessment using faecal 111 in granulocyte excretion. Digestion 33: 74-79
5. Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2): 1-5
6. D'Haens G et al. (1997) Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112: 1475-1481
7. D'Haens G et al. (1999) Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 50: 667-671
8. Bitton A et al. (2001) Clinical, biological, and histologic parameters as predictors relapse in ulcerative colitis. Gastroenterology 120: 13-20
9. Modigliani R (1994) Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 89 (Suppl 8): S53-S65
10. Vermeire S et al. (2001) Comparative study of ASCA (anti- Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 120: 827-33
11. Sandborn WJ et al. (2001) Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 7: 192-201
12. Poullis A et al. (2002) Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 16: 675-681
13. Johne B et al. (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 50: 113-123
14. Roseth AG et al. (1992) Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27: 793-798
15. Roseth AG et al. (1997) Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58: 176-180
16. Roseth AG et al. (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34: 50-54
17. Tibble J et al. (2000) A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47: 506-513
18. D'Haens G et al. (2002) Endoscopic healing after Infliximab treatment for Crohn's disease provides a longer time in relapse. Gastroenterology 122 (suppl): A100
19. Roseth AG et al. (2004) Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39: 1017-1020
20. Tibble JA et al. (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15-22
21. Costa F et al. Calprotectin is a stronger predictive markers of relapse in ulcerative colitis than in Crohn's disease. Gut (in press)
22. Limburg PJ et al. (2000) Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 95: 2831-2837
23. Levay PF and Viljoen M (1995) Lactoferrin: a general review. Haematologica 80: 252-267
24. Fine KD et al. (1998) Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 93: 1300-1305
25. Kane SV et al. (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98: 1309-1314
26. Poulis A et al. (2004) Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 13: 279-284
27. Perner A and Rask-Madsen J (1999) Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Aliment Pharmacol Ther 13: 135-144
28. Lundberg JO et al. (1997) Nitric oxide and inflammation: the answer is blowing in the wind. Nat Med 3: 30-31
29. Lundberg JO et al. (1994) Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 344: 1673-1674
30. Herulf M et al. (1998) Increased luminal nitric oxide in inflammatory bowel disease as shown with a novel minimally invasive method. Scand J Gastroenterol 33: 164-169
31. Herulf M (2001) Luminal Nitric Oxide: Markers of Intestinal Inflammation [thesis]. Karolinska Institutet, Stockholm
32. Canani RB et al. (2002) Nitric oxide production in rectal dialysate is a marker of disease activity and location in children with inflammatory bowel disease. Am J Gastroenterol 97: 1574-1576
33. Perner A et al. (2002) Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol 37: 183-188
34. Ljung T et al. (2002) Increased rectal nitric oxide in children with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 34: 302-306
35. Ljung T et al. (2001) Rectal nitric oxide assessment in children with Crohn disease and ulcerative colitis. Indicator of ileocaecal and colorectal affection. Scand J Gastroenterol 36: 1073-1076
36. Herulf M et al. (1999) Increased nitric oxide in infective gastroenteritis. J Infect Dis 108: 542-545
37. Lundberg JO et al. (1997) Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest 27: 869-871
38. Olesen M et al. (2003) Luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis. Scand J Gastroenterol 38: 66-72
39. Enocksson A et al. (2004) Rectal nitric oxide gas and stool cytokine levels during the course of infectious gastroenteritis. Clin Diagn Lab Immunol 11: 250-254
40. Soop A et al. (2003) Exhaled NO and plasma cGMP increase after endotoxin infusion in healthy volunteers. Eur Respir J 21: 594-599
41. Singer II et al. (1996) Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111: 871-885
42. Fagerhol MK (2000) Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 356: 1783-1784
43. Camilleri M (2001) Management of the irritable bowel syndrome. Gastroenterology 120: 652-668
44. Tibble JA et al. (2002) Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123: 450-460
45. Olesen M et al. (2004) Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 53: 346-350
46. Nielsen OH et al. (2004) Microscopic colitis: a missed diagnosis? Lancet 364: 2055-2057
47. Bunn SK et al. (2001) Fecal calprotectin: validation as a nonivasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33: 14-22
48. Fagerberg UL et al. (2003) Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 37: 468-472
49. Olafsdottir E et al. (2002) Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 91: 45-50
50. Sobko T et al. Birth-related changes in intracolonic nitric oxide and hydrogen gas. Allergy (in press)
51. Menchen L et al. (2004) Activity of inducile and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis. Am J Gastroenterol 99: 1756-1764
52. Colon AL et al. (2000) Inducible nitric oxide synthase activity is expressesd not only in inflamed but also in normal colonic mucosa in patients with ulcerative colitis: a potential prognostic marker. Am J Gastroenterol 95: 1371-1373